Search PubMed⌕ Search

Biomedical subjects

F Bach

Publications and source records attributed to F Bach.

71 records · Page 4Linked to original sources
PubMed1985

Frequency, diagnosis, and prognosis of spinal cord compression in small cell bronchogenic carcinoma. A review of 817 consecutive patients.

A retrospective review of 817 consecutive patients with small cell bronchogenic carcinoma disclosed 29 cases of spinal cord compression (frequency, 3.5%). Twelve patients (group 1) presented with symptom of cord compression, whereas the remaining 17 patients (group 2) developed this complication during therapy. Clinical features differed in the two groups: pain was present in 83% of the patients in group 1 and in 47% of those in group 2. Pain preceded motor dysfunction in 75% and 12% of the two groups, respectively. Radiologic bone destruction of the spine was found in 11 of 12 patients in group 1 and in 3 of 16 patients in group 2. Myelography was performed in 8 patients in group 1 and in 14 patients from group 2. A complete block was found in seven and none of the patients in each of the two groups, respectively. Treatment with irradiation and/or laminectomy rarely resulted in a significant improvement of preexisting neurologic impairment but it frequently prevented the progression of symptoms, leading to preservation of sphincter control and ambulatory function in eight of nine and seven of eight patients, respectively. Careful evaluation is mandatory for patients presenting with back pain and radiographic evidence of bone destruction, as 11 of 26 such patients were found to have spinal cord compression. It is concluded that spinal cord compression presents in two distinct ways. One with early onset, pain, evidence of bone destruction, and complete myelographic block. The second is characterized by motor impairment with no evidence of bone destruction and only partial myelographic block. Treatment rarely ameliorates symptoms but prevents deterioration, making early diagnosis important.

Carcinoma, Bronchogenic↗
PubMed1985

Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent.

1,2,4-Triglycidylurazol, a new triepoxide derivative, was chosen for phase I trial because of its favorable water solubility, stability and antitumor activity in murine systems. Fifty-seven patients were evaluable. Hematologic toxicity was dose-limiting, with a steep dose-toxicity curve. At 650 mg/m2 2/10 patients developed grade II toxicity. Seventeen patients were treated at 800 mg/m2 and seven developed grade III or IV toxicity according to WHO. Five of these patients had received greater than 3 cytotoxic agents and/or extensive radiotherapy. One toxic death was seen. Cumulative toxicity was observed with respect to hematologic values in a comparison of the first and second courses. Sixteen patients developed phlebitis after injection, not dose-dependent and not dose-limiting. Response was noted in three patients, two non-small cell lung cancers and one bladder cancer. Recommended doses for phase II trials are 800 mg/m2 q 4 weeks for patients who have received less than or equal to 3 cytotoxic agents and 650 mg/m2 q 4 weeks for heavily pretreated patients.

Adult↗
PubMed1985

Effect of cold exposure on liver and muscle cAMP content and cAMP phosphodiesterase activity.

Adenosine 3',5'-cyclic monophosphate (cAMP) concentration and 3',5'-cyclic-nucleotide phosphodiesterase (PDE) activity were measured in skeletal muscle, heart, and liver of rats exposed to 1, 3, 5, and 7 days of cold. Cyclic nucleotide concentration increased in fast-twitch red muscle at the same time that PDE activity was decreasing. Nucleotide concentration and enzyme activity of slow-twitch red muscle were not altered by the cold exposure. The PDE activity of fast-twitch white muscle was elevated approximately 50% above control after 1 and 3 days of cold exposure. By the 5th day in the cold, white muscle PDE activity had returned to control levels and remained there through the 7th day of experimentation. cAMP concentration in hearts of cold-exposed rats was significantly (P less than 0.01) elevated above control at all time points measured. Myocardial PDE activity was elevated above control (P less than 0.05) at 1 and 3 days of cold exposure but returned to control levels by the 5th day in the cold. Hepatic cAMP and PDE activity were elevated above control at all time points analyzed. These data suggest that changes in cyclic nucleotide metabolism play a role in attaining homeostasis during acute cold exposure.

3',5'-Cyclic-AMP Phosphodiesterases↗
PubMed1985

Creatine kinase BB and beta-2-microglobulin as markers of CNS metastases in patients with small-cell lung cancer.

Creatine kinase (CK) and its BB isoenzyme (CK-BB) were measured in CSF in 65 evaluable patients suspected of CNS metastases secondary to small-cell lung cancer (SCLC). In addition, CSF and plasma levels of beta-2-microglobulin (beta-2-m) were measured in a group of 73 evaluable patients. Of the 65 patients analysed for CK-BB, 17 had meningeal carcinomatosis (MC), 26 had parenchymal metastases only, and 22 had no CNS disease. Patients with MC had a significantly higher CK-BB concentration in CSF than did patients belonging to the other two groups (P less than .01). Taking 0.4 U/L (upper limit in patients without CNS disease) as a cut-off point, 15 patients (88%) with MC had elevated CSF concentrations of CK-BB. Patients without CNS metastases had no CSF levels exceeding this value, whereas five patients with multiple CNS metastases did. Receiver operating characteristic (ROC) analysis suggests that CK-BB may be useful in distinguishing MC among patients suspected of having CNS metastases, and CK-BB appears superior to total CK, CSF protein, and CSF lactic dehydrogenase (LDH). In 12 patients with MC at autopsy, CK-BB was, with the above cut-off point, elevated in six patients with a false negative cytology. Of the 73 patients examined for beta-2-m, 18 had MC, 30 had parenchymatous metastases only, and 25 patients had no CNS metastases. The CSF concentrations in the three groups were not significantly different. The median concentrations in the groups were 133 nmol/L, 125 nmol/L, and 107 nmol/L, respectively. The ratios between beta-2-m in CSF and plasma were also not significantly different between the three groups. Thus, the data on CK-BB are promising, and further studies are warranted to see if the usefulness of CK-BB can be more firmly established. By contrast, beta-2-m has no role as a marker of CNS disease secondary to SCLC.

Brain Neoplasms↗
PubMed1985

Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.

The effect of doxorubicin and cyclophosphamide in the treatment of diffuse, malignant pleural mesothelioma was evaluated in a randomized study. All patients were treated on an outpatient basis and none had previously received antineoplastic treatment. All patients had a measurable lesion other than pleural effusion. The treatment consisted of doxorubicin at a dose of 60 mg/m2 every 3 weeks, to a total dose of 550 mg/m2, or cyclophosphamide at a dose of 1500 mg/m2 every 3 weeks for 1 year. At disease progression the treatment was changed to the alternate drug. The dose was increased or decreased according to hematologic effects. Thirty of 32 patients were evaluable for response. Remissions were not achieved in any patient. During treatment with doxorubicin, none of the patients developed cardiotoxicity, while one patient developed hemorrhagic cystitis during treatment with cyclophosphamide. Sepsis or bleeding was not observed in either of the treatment arms. Thus, the trial showed no antineoplastic activity of either doxorubicin or cyclophosphamide in the treatment of malignant pleural mesothelioma.

Aged↗
PubMed1984

Surgical management of intestinal obstruction in the late course of malignant disease.

Intra-abdominal and pelvic malignancies not infrequently are complicated by intestinal obstruction during their progressive course. How energetically this complication should be treated is a matter of controversy. An analysis of 41 such cases is presented. Small-bowel obstruction was most commonly caused by extensive serosal carcinomatosis, whereas obstruction of the large bowel usually was due to a single tumor. There was good concordance between the preoperative assessment of blockage level (small v. large bowel) and peroperative findings. All the patients with colonic obstruction obtained palliation from surgery, with median duration 6 months. Only 63% of the patients with small-bowel obstruction were relieved. This figure fell to 44%, with median duration of relief only 2 months, when carcinomatosis was the causal condition. The corresponding figures for patients with block caused by a single tumor were 89% and 6 months. Intestinal obstruction from non-malignant mechanisms was relieved in all cases. Surgical exploration should be attempted in these patients, as conservative measures are known to be of little benefit. In patients with extensive carcinomatosis, however, a favorable outcome in terms of symptom relief and prolonged survival is relatively unlikely.

Adolescent↗
PubMed1978

Assessment of a diagnostic dip-stick for assaying plasma or serum pseudocholinesterase activity.

A diagnostic dip-stick for measuring pseudocholinesterase activity has been assessed by 4 participants and compared with a standard spectrophotometric method. Duplicate dip-stick estimations (measured in kU/l) corresponded closely, and concurrence between participants was good. The dip-stick estimate of cholinesterase was consistently lower than the spectrophotometric value; the magnitude of this deviation depended on the absolute enzyme activity. With enzyme activities of up to 1 kU/l the dip-stick value was 1 unit lower. Between 1 and 4 kU/l the dip-stick estimate compared well with the spectrophotometric value. From 5 to 7 kU/l and beyond 7 kU/l the negative deviation recorded by the dip-stick increased to 2 units or more. Normal enzyme activity is 3 - 6 kU/l. Over the 1 - 4 kU/l range the method is most accurate, thus negative deviation below 1 kU/l or above 4 kU/l is generally diagnostically irrelevant. On the basis of cost, convenience, speed and accuracy this method will suffice in the absence of sophisticated assay facilities.

Apnea↗
PubMed1977

Prediction of renal allograft rejection by direct lymphocyte blastogenesis assay.

In an effort to better predict renal allograft rejection, lymphocyte blastogenesis (DLBA) was determined in 65 patients after transplants. Of 47 clinically diagnosed rejection episodes 45 had an associated DLBA peak which preceded the clinical diagnosis by an average of 4 days; 11 recipients had DLBA peaks not associated with rejection episodes. Of 14 recipients with multiple DLBA peaks during postoperative periods of nonfunction, none did well. The blastogenesis assay was not a reliable enough predictor of graft rejection to be used as an indication for early elevation of corticosteroid dosage.

Graft Rejection↗
PubMed1972

Rehabilitation.

Explore the source record for details and available documents.

Physical and Rehabilitation Medicine↗